News

Deal Announcements

Cara Therapeutics Lands $12 Million Series C Funding

Monday, July 28, 2008 5:46:00 AM PDT | VentureDeal Staff
Shelton, Connecticut --  Biotechnology company Cara Therapeutics announced that it has raised $12.3 million in additional series C funding.

Cara is focused on developing therapeutics to treat diseases associated with acute pain and inflammation.  The company's first patented compound, CR665, has entered clinical testing.

Investors in the round included lead investor Devon Park BioVentures as well as Ascent Venture Partners, Mitsubishi Corp., Scottish Widows Investment Partnership, MVM Life Science Partners and Alta Partners.

The company said that the additional funds will be used for its second-generation opioid agonist, CR845.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1